Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APELINS-2: Apelin in Type 2 Diabetes
NCT02724566Phase 1Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of apelin-13 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Glucose Infusion Rate at 240 minutes. Started May 2016; status: completed.
02
Drugs
apelin-13
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02724566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724566.